Log in

Healthcare

Trial data, approvals, and what they are worth

Readouts, FDA decisions, drug pricing and payer behaviour, sized in revenue rather than in press-release adjectives.

What Big Funds Own42 fundsWhat Berkshire, Bridgewater and other big funds reported holding last quarter.What Analysts Expect16 stocksRatings and price targets from the big institutions, each with its public source.

2026-08-04

Eli Lilly's “Early-Access” Move Is a TAM Pre-Pricing Mechanism insight cover
Earnings
LLY•8 min read

Eli Lilly's “Early-Access” Move Is a TAM Pre-Pricing Mechanism

Lilly’s “early access” to its next-gen obesity drug (retatrutide) is not charity—it is a controlled go-to-market rehearsal that can pre-price demand and steer where patients (and cash-pay channels) land once the broader launch hits. In this model, the value comes from learning-and-pricing ahead of approval, while the financials show Lilly can fund growth and scale investment despite periods of low free cash flow.

Weight loss at 80 weeks (12 mg vs placebo): -28.3% vs -2.2%≥30% weight loss (12 mg): 45.3%
Read article
Merck's “Quarter Beat” Is a Patent-Reset Reality Check insight cover
Earnings
MRK•7 min read

Merck's “Quarter Beat” Is a Patent-Reset Reality Check

Merck’s latest reported strength shows how much the Keytruda franchise can still carry, but it doesn’t answer the real question: whether Merck has built a durable replacement economics model before biosimilar pressure starts in December 2028. The company also guided FY2026 sales upward into a window that still precedes the hardest 2028–2029 exclusivity step-down.

Keytruda/Keytruda QLEx (1Q 2026): $8.0BFY2026 sales outlook (range): $65.8B–$67.0B
Read article
Pfizer's $2.5B save is the easy part; the question is what it funds after the patent cliff insight cover
Earnings
PFE•9 min read

Pfizer's $2.5B save is the easy part; the question is what it funds after the patent cliff

Pfizer has repeatedly expanded its “cost realignment” targets, with the program originally including at least $2.5B of additional net savings expected to be realized in 2024 and later culminating in ~$5.7B through 2026. The hard investor question is whether these savings are protecting (or crowding out) the cash needed for the post-patent-cliff commercial and pipeline reset.

Operating cash flow (FY2025): $11.7BFree cash flow (FY2025): $9.1B
Read article
Procter & Gamble's $3.8B Thorne bet shifts “wellness” from shelf risk to premium supply-chain leverage insight cover
Industry News
PG•7 min read

Procter & Gamble's $3.8B Thorne bet shifts “wellness” from shelf risk to premium supply-chain leverage

Procter & Gamble is reportedly paying $3.8B in cash to acquire Thorne, a science-driven supplements brand, with closing expected later in 2026. The investor question is not “does supplements grow?”—it’s whether P&G can add a higher-growth, higher-trust revenue stream without sacrificing the margin discipline that supports its staple-like cash generation.

FY2026 revenue: $87.0BFY2026 net income: $18M
Read article
Waters’ Forecast Raise Suggests Biopharma Labs Are Moving Past a One-Quarter “Freeze” insight cover
Earnings
7 min read

Waters’ Forecast Raise Suggests Biopharma Labs Are Moving Past a One-Quarter “Freeze”

Waters’ 2026 guidance raise points to demand that’s not just cyclical—especially because it ties growth to diagnostics and lab equipment rather than a broad market normalization. The investor question is whether this becomes a durable replacement/utilization cycle that pulls through consumables and services, or whether it fades as budgets reset.

TTM Revenue: $3.770BTTM Gross Profit: $2.074B
Read article

2026-08-03

AstraZeneca–Bristol Myers’ alleged $400B oncology tie-up isn’t about synergy—it’s about buying back the “patent-cliff premium” investors demand insight cover
Industry News
AZN · BMY•8 min read

AstraZeneca–Bristol Myers’ alleged $400B oncology tie-up isn’t about synergy—it’s about buying back the “patent-cliff premium” investors demand

If the reported AstraZeneca–Bristol Myers Squibb (BMS) $400B megadeal ever advanced, the first re-pricing would be in oncology patent-cliff expectations: BMS’s revenue concentration in Opdivo and Eliquis LOE risk would effectively get capitalized into the combined group. The deal logic is strongest for BMS because Eliquis exposure is structurally harder to replace than label-expanding immuno-oncology, which forces a buyer-of-last-resort dynamic that would ripple into how investors price other “patent cliff” stories.

AstraZeneca revenue trend (annual): $58.739B (2025)Bristol Myers Squibb revenue trend (annua: $48.195B (2025)
Read article
Curium’s Lantheus bid is really an isotope-capacity bet—because radiopharma growth is constrained by reactors, not chemistry insight cover
Supply Chain
7 min read

Curium’s Lantheus bid is really an isotope-capacity bet—because radiopharma growth is constrained by reactors, not chemistry

Curium’s reported pursuit of Lantheus shows radiopharma is shifting from “drug + distribution” to “drug + isotope throughput.” The investment implication is that bidders can gain durable advantage only by securing upstream nuclear capacity and locking down downstream commercial pull.

Event Date: 2026-08-03Topic Type: Supply Chain
Read article
Eli Lilly's “cancer win” narrows the addressable audience—and that’s the real 2027 oncology TAM reset insight cover
Earnings
LLY · BMY•7 min read

Eli Lilly's “cancer win” narrows the addressable audience—and that’s the real 2027 oncology TAM reset

Lilly’s latest oncology positive readout is a genuine efficacy win, but it’s tethered to a biomarker-defined subgroup (RET fusion–positive NSCLC), which shrinks commercial TAM versus “all-comers.” That subgroup math forces a sharper rerate framework for Eli Lilly, changes the opportunity-cost lens on Bristol-Myers Squibb, and matters disproportionately for smaller targeted-oncology platforms like Arvinas and Black Diamond Therapeutics.

Lilly revenue (TTM): $72.25BLilly net income (TTM): $25.28B
Read article
Novo Nordisk ‘claws back’ into obesity because the market is shifting from injections-only to pills-and-next-gen demand insight cover
Industry News
NVO · LLY•8 min read

Novo Nordisk ‘claws back’ into obesity because the market is shifting from injections-only to pills-and-next-gen demand

Novo Nordisk’s obesity narrative is being re-rated around oral GLP-1 execution (including Wegovy pills) rather than only injection leadership—exactly the demand shift that can loosen Lilly’s pricing power. The setup matters because Eli Lilly still trades like a monopoly ($40.8x trailing P/E), while the Reuters-driven “pipeline reset” forces investors to price a wider share of the obesity wallet into Novo’s future.

Novo Nordisk trailing P/E: 11.21xEli Lilly trailing P/E: 40.81x
Read article

2026-08-02

Moderna Cleared the Science Test; August 5 Will Price the Policy Test insight cover
Earnings
MRNA · BNTX•12 min read

Moderna Cleared the Science Test; August 5 Will Price the Policy Test

Moderna's mFlusiva produced 26.6% relative efficacy over a standard flu shot and won unanimous FDA-adviser support, but approval is no longer the only hurdle. HHS has terminated 22 mRNA investments worth nearly $500 million, making recommendation, distribution and uptake the harder tests for Moderna—and the more important read-through for BioNTech and Pfizer.

FDA deadline: Aug. 5Advisory vote: 9–0
Read article

2026-08-01

Replimune Just Doubled After a 10-3 Vote — That's Not the Story. The Story Is That Two FDA Rejections Just Became One Approval insight cover
Earnings
REPL · CAPR•13 min read

Replimune Just Doubled After a 10-3 Vote — That's Not the Story. The Story Is That Two FDA Rejections Just Became One Approval

An FDA panel voted 10-3 on July 30, 2026, that Replimune Group's twice-rejected RP1+nivolumab data were 'evaluable and clinically meaningful,' sending shares up ~128% premarket to $12.44 against a ~$5.41 close. The PDUFA date is August 2, 2026, with the panel win coming one day after the same committee voted 9-3 against Capricor's deramiocel — proving that 2026 adcom outcomes now split cleanly on trial design, not on ideological FDA priors. The deeper read: Vinay Prasad is gone, Marty Makary is out, and the agency is being run by an acting commissioner who has not yet telegraphed a stance, which paradoxically raises the floor on biotech downside-skew bets.

CTGTAC vote (RP1 efficacy): 10-3REPL premarket move: +~128%
Read article
The UFLPA’s 43-Company Expansion Turns Supply-Chain Proof Into a Cross-Industry Cost insight cover
Policy Trade
15 min read

The UFLPA’s 43-Company Expansion Turns Supply-Chain Proof Into a Cross-Industry Cost

DHS added 43 China-based companies to the UFLPA Entity List on July 31, bringing the total to 187 and making the restriction materially broader than an apparel-only issue. The immediate risk is not a blanket tariff: it is shipment detention, denied entry, supplier replacement and documentation costs for importers using aluminum, metals, battery materials, food or electronics linked to the listed entities.

New entities: 43Consolidated list: 187
Read article
Retail Captures the GLP-1 Script: Walmart, Costco, and Amazon Siphon $14B of High-Margin Cash-Pay From PBMs insight cover
Industry News
WMT · COST•14 min read

Retail Captures the GLP-1 Script: Walmart, Costco, and Amazon Siphon $14B of High-Margin Cash-Pay From PBMs

Three retailers — Walmart, Costco, and Amazon — now dispense oral GLP-1s from $25 insured and $149 cash-pay, while the July 1 Medicare GLP-1 Bridge sends $50 scripts through their counters just as 10% of large employers drop coverage for 2027. The shift reroutes billions in rebate-eligible prescriptions around CVS Health Caremark and UnitedHealth OptumRx, and forces independent and chain pharmacies like Walgreens to fill GLP-1s at a loss. The structural read-through: branded volumes to Eli Lilly and Novo Nordisk hold up, but PBM rebate economics, telehealth disruptors like Hims & Hers, and price-discovery platforms like GoodRx all lose pricing power and per-script margin simultaneously.

Event Date: 2026-08-01Topic Type: Industry News
Read article

2026-07-31

Novo's ZEUS Heart-Drug Flop Doesn't Kill the GLP-1 Trade — It Redraws the Obesity Stack's Power Lines insight cover
Industry News
NVO · LLY•15 min read

Novo's ZEUS Heart-Drug Flop Doesn't Kill the GLP-1 Trade — It Redraws the Obesity Stack's Power Lines

Novo Nordisk lost ~$30B in market cap Friday after ziltivekimab — an anti-IL-6 antibody, not a GLP-1 — flunked its 6,300-patient ZEUS cardiovascular outcomes trial with a hazard ratio of 0.99. The bigger story is what the failure reveals: the cardiovascular label is going to be won by GLP-1 mechanism drugs (where Eli Lilly already owns the SUMMIT HFpEF data), not by anti-inflammatory add-ons. With HERMES and ARTEMIS still reading out in H1 2027, the GLP-1 trade pivots from TAM to indication-by-indication — and the supply chain that picks up the slack is concentrated in three US wholesalers and a few CDMO champions.

Novo Nordisk trailing P/E: 12.2xEli Lilly trailing P/E: 42.9x
Read article

2026-07-30

Haleon’s H1 “US slip / Oral Health win” reframes the staples trade into a category bet insight cover
Earnings
8 min read

Haleon’s H1 “US slip / Oral Health win” reframes the staples trade into a category bet

Haleon reaffirmed full-year guidance, but H1’s internal split matters: Oral Health delivered mid-single-digit growth while North America slowed versus stronger Emerging Markets. For investors running “premium staples” pair trades, the earnings print shifts the question from “staples resilience” to “which category compounds when the US consumer softens.”

H1 2026 organic revenue: 2.6%H1 2026 revenue: £5,602m
Read article
Johnson & Johnson's FY2026 EPS guide drops ~5% on deal/integration costs—proof the pharma M&A cycle is now a P&L story insight cover
Earnings
JNJ•7 min read

Johnson & Johnson's FY2026 EPS guide drops ~5% on deal/integration costs—proof the pharma M&A cycle is now a P&L story

After beating in Q2, Johnson & Johnson still cut FY2026 adjusted EPS guidance to $10.96–$11.11, attributing the reset to integration/transaction costs. The signal is broader than one quarter: the 2026–2027 healthcare earnings template is shifting from “pipeline-shaped upside” to “M&A-shaped near-term earnings pressure,” with investors needing to separate one-time deal costs from underlying franchise health.

FY2026 adjusted EPS (new guide): $10.96–$11.11FY2026 adjusted EPS (prior guide): $11.60–$11.75
Read article

2026-07-29

Boston Scientific bets on cost cuts as WATCHMAN mix risk rises—how to separate restructuring alpha from franchise dilution insight cover
Earnings
BSX•9 min read

Boston Scientific bets on cost cuts as WATCHMAN mix risk rises—how to separate restructuring alpha from franchise dilution

Boston Scientific’s cost-savings program targets ~$500M annual expense reduction after a $700M–$800M charge window, but it comes while management flagged a 2026 headwind tied to Watchman stand-alone procedure usage. Investors should track whether restructuring-generated operating leverage can offset a shift from “stand-alone” to “bundled” cardiac workflows that can compress product-mix value per procedure at the margin.

Restructuring plan approval date: Jul 21, 2026Expected pre-tax restructuring charges: $700M–$800M
Read article
FTC’s Hims & Hers Pixel Case Makes Meta and Snap the Real Compliance Bottleneck for Telehealth PHI Advertising insight cover
Industry News
META · SNAP•8 min read

FTC’s Hims & Hers Pixel Case Makes Meta and Snap the Real Compliance Bottleneck for Telehealth PHI Advertising

The FTC (with LA County and Utah) alleges Hims & Hers sent sensitive health data to Meta and Snap pixel tracking systems used for ad targeting/measurement. The key shift for investors is that the “HIPAA pixel loophole” becomes a de facto gatekeeping constraint on the entire consumer-telehealth ad-tech stack—raising compliance, remediation, and potential usage-cost risks for Meta META and Snap SNAP alongside the advertiser.

Hims & Hers Health, Inc. FY revenue: $2.35BHims & Hers Health, Inc. FY net income: $0.13B
Read article

2026-07-28

Boston Scientific’s $700–800M restructuring is a multi-year operating-leverage bet: the $500M annualized savings math has to land by 2029 insight cover
Earnings
BSX•8 min read

Boston Scientific’s $700–800M restructuring is a multi-year operating-leverage bet: the $500M annualized savings math has to land by 2029

Boston Scientific BSX approved a 2026–2029 restructuring with ~$700–$800M of pre-tax charges and ~$500M of annualized gross expense reduction, including ~$600–$700M in future cash outlays. The strategic read-through is that this is meant to reconfigure manufacturing and supply-chain footprint for margin expansion—not just cut costs—so 2027 peer comparisons will hinge on how much of the savings the company actually realizes versus the one-time spend.

FY revenue (baseline): $20.1BOperating income (baseline): $4.0B
Read article
GSK's $2.5B savings drive is really a pipeline-reliability budget—so the market should price its R&D conversions, not just “patent cliff” cuts insight cover
Industry News
GSK•7 min read

GSK's $2.5B savings drive is really a pipeline-reliability budget—so the market should price its R&D conversions, not just “patent cliff” cuts

GSK’s announced cost-savings drive is framed as funding its pipeline by improving R&D productivity and execution timing, not merely extending cash via patent protection. That shifts the reinvestment math: investors should watch whether pipeline risk-adjacent value is rising fast enough to justify sustained R&D spend and commercial intensity.

FY2025 revenue: £32.7BFY2025 R&D expense: £7.5B
Read article

What to expect

Evidence-first notes with a visible point of view.

This section collects sharp takes on earnings, shareholder meetings, and market structure. Each new piece should make the thesis, the facts, and the implications obvious within the first few screens.

Expect direct analysis, not generic commentary.

Expect the data to be explicit and the argument to be easy to follow.